Blind-Watermarking-Proof-of-Concept of a Novel Approach to Ensure Batch Traceability for 3D Printed Tablets.

FDM 3D printing anti-counterfeiting blind-watermarking falsified medicine personalized medicine traceability

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
17 Feb 2022
Historique:
received: 20 01 2022
revised: 07 02 2022
accepted: 14 02 2022
entrez: 26 2 2022
pubmed: 27 2 2022
medline: 27 2 2022
Statut: epublish

Résumé

Falsified medicines are a major issue and a threat around the world. Various approaches are currently being investigated to mitigate the threat. In this study, a concept is tested that encodes binary digits (bits) on the surface of Fused Deposition Modelling (FDM) 3D printed geometries. All that is needed is a computer, a FDM 3D printer and a paper scanner for detection. For the experiments, eleven different formulations were tested, covering the most used polymers for 3D printing in pharma: Ethylene-vinyl acetate (EVA), polyvinyl alcohol (PVA), polylactic acid (PLA), Hypromellose (HPMC), ethyl cellulose (EC), basic butylated-methacrylate-copolymer (EPO), and ammonio-methacrylate-copolymer type A (ERL). In addition, the scanning process and printing process were evaluated. It was possible to print up to 32 bits per side on oblong shaped tablets corresponding to the dimensions of market preparations of oblong tablets and capsules. Not all polymers or polymer blends were suitable for this method. Only PVA, PLA, EC, EC+HPMC, and EPO allowed the detection of bits with the scanner. EVA and ERL had too much surface roughness, too low viscosity, and cooled down too slowly preventing the detection of bits. It was observed that the addition of a colorant or active pharmaceutical ingredient (API) could facilitate the detection process. Thus, the process could be transferred for 3D printed pharmaceuticals, but further improvement is necessary to increase robustness and allow use for more materials.

Identifiants

pubmed: 35214164
pii: pharmaceutics14020432
doi: 10.3390/pharmaceutics14020432
pmc: PMC8879528
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Federal Ministry of Education and Research
ID : 13XP5064B

Références

Drug Saf. 2018 Oct;41(10):911-918
pubmed: 29721822
J Infect Dis. 2019 Jan 29;219(4):672-673
pubmed: 30307565
AAPS PharmSciTech. 2018 Nov;19(8):3333-3342
pubmed: 29855799
Int J Pharm. 2019 Oct 5;569:118581
pubmed: 31369828
Int J Pharm. 2017 Jul 15;527(1-2):21-30
pubmed: 28502898
Am J Health Syst Pharm. 2014 Feb 1;71(3):209-18
pubmed: 24429014
Clin Med (Lond). 2009 Feb;9(1):63-4
pubmed: 19271604
Int J Pharm. 2021 Mar 15;597:120235
pubmed: 33549813
Ther Innov Regul Sci. 2021 Nov 26;:
pubmed: 34826120
Int J Pharm. 2019 Aug 15;567:118443
pubmed: 31212052
Pharmaceutics. 2021 Nov 04;13(11):
pubmed: 34834272
Nurs Womens Health. 2018 Jun;22(3):264-268
pubmed: 29885715
J Vector Borne Dis. 2019 Oct-Dec;56(4):288-294
pubmed: 33269727
Nature. 2016 Sep 07;537(7619):S49
pubmed: 27602738
Lancet. 2001 Mar 17;357(9259):890
pubmed: 11265991
J Pharm Sci. 2019 Sep;108(9):2838-2841
pubmed: 31054889
Pharmaceutics. 2021 Sep 11;13(9):
pubmed: 34575529
Expert Rev Anti Infect Ther. 2016 Jun;14(6):531-3
pubmed: 27187060
N Engl J Med. 2010 Jul 22;363(4):301-4
pubmed: 20551152
BMJ Glob Health. 2020 Aug;5(8):
pubmed: 32859648
Eur J Pharm Sci. 2016 Jul 30;90:53-63
pubmed: 26545484
Int J Pharm. 2021 Mar 15;597:120216
pubmed: 33493597
Int J Pharm. 2020 Sep 25;587:119702
pubmed: 32736015
Pharm Dev Technol. 2018 Dec;23(10):1117-1127
pubmed: 29368974
Analyst. 2011 Aug 7;136(15):3073-82
pubmed: 21107455
Pharmaceutics. 2020 Jun 03;12(6):
pubmed: 32503216
Nat Rev Genet. 2016 Aug 16;17(9):507-22
pubmed: 27528417
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 Nov;60(11):1188-1195
pubmed: 28929177
Int J Pharm. 2018 Jan 30;536(1):138-145
pubmed: 29183858
Expert Rev Anti Infect Ther. 2015 Apr;13(4):505-9
pubmed: 25683870
Health Policy Plan. 2016 Dec;31(10):1448-1466
pubmed: 27311827
Pharmaceutics. 2021 Dec 03;13(12):
pubmed: 34959349
J Control Release. 2021 Feb 10;330:821-841
pubmed: 33130069
Int J Pharm. 2021 Aug 10;605:120793
pubmed: 34119582
Pharmaceutics. 2022 Jan 17;14(1):
pubmed: 35057112
Int J Pharm. 2021 Dec 15;610:121194
pubmed: 34728321
Global Health. 2021 Sep 23;17(1):114
pubmed: 34556126
Lancet. 2003 Jul 12;362(9378):169
pubmed: 12867121
Lancet. 2015 Oct 3;386(10001):1327-8
pubmed: 26460765
Int J Pharm. 2021 Dec 15;610:121261
pubmed: 34742830
J Drug Deliv Sci Technol. 2019 Aug;52:292-302
pubmed: 32855657
Pharmaceuticals (Basel). 2021 May 01;14(5):
pubmed: 34062744
Adv Drug Deliv Rev. 2021 May;172:52-63
pubmed: 33571550
J Control Release. 2018 Jan 10;269:355-363
pubmed: 29146240

Auteurs

Hellen Windolf (H)

Institute of Pharmaceutics and Biopharmaceutics, Heinrich Heine University, Universitätsstr. 1, 40225 Düsseldorf, Germany.

Rebecca Chamberlain (R)

Institute of Pharmaceutics and Biopharmaceutics, Heinrich Heine University, Universitätsstr. 1, 40225 Düsseldorf, Germany.

Arnaud Delmotte (A)

Optical Media Interface Laboratory, Nara Institute of Science and Technology, 8916-5 Takayama-cho, Nara 630-0192, Japan.

Julian Quodbach (J)

Institute of Pharmaceutics and Biopharmaceutics, Heinrich Heine University, Universitätsstr. 1, 40225 Düsseldorf, Germany.
Department of Pharmaceutical Sciences, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands.

Classifications MeSH